Two physicians who co-founded Fullerton Healthcare Corporation have been ordered to pay a combined penalty of S$160,000 after pleading guilty to falsifying corporate expense documentation in Singapore. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52 years old, appeared before the courts on Friday (July 10) to receive their sentences, stemming from a complex scheme involving inflated entertainment receipts spanning several years. The case represents the latest in a series of high-profile corporate misconduct prosecutions involving the healthcare investment holding company, exposing internal financial controls failures at a firm that operates across multiple subsidiaries across Asia.
Chan received the heavier penalty of S$135,000 after confessing to five counts of falsifying accounts, while Tan faced a S$25,000 fine for a single falsification charge. The disparity in their sentences reflects the markedly different scales of their individual involvement in the scheme. Chan's falsified claims accumulated to over S$336,000, with legitimate underlying expenses merely totalling approximately S$125,000, producing an inflated margin exceeding S$211,000. Tan's falsification involved a single entertainment claim of approximately S$82,000 against actual expenses of over S$42,000, yielding an inflated difference of nearly S$40,000. Both physicians had entered guilty pleas two days prior on July 8, streamlining proceedings and avoiding prolonged courtroom disputes.
Crucially, neither Chan nor Tan derived personal financial benefit from these manipulations. The proceedings revealed that the entire fraudulent apparatus served to channel funds toward Collin Chiew, a 58-year-old who previously held the position of chief executive officer at insurance broker Aon Singapore between January 2015 and July 2018. Court documentation indicated that Chiew requested financial assistance from Chan in 2015, citing personal needs related to his children and residential property expenses. Rather than declining, Chan consulted with Tan about accommodating Chiew's request, setting in motion a years-long pattern of falsified documentation designed to extract corporate funds ostensibly earmarked for entertainment purposes.
The scheme operated through a methodical process beginning around 2015, when Chan commenced frequent business trips to Hong Kong occurring approximately twice monthly to advance FHC's regional operations. Before each journey, he would contact David Sin, another co-founder, requesting inflated or fabricated KTV receipts to be prepared by Tei Chu Pink, a 46-year-old associate. During his Hong Kong visits, Chan would attend karaoke establishments alongside Sin and Tei, purportedly meeting prospective investors, though on numerous occasions he contributed nothing to the actual entertainment expenses. Sometimes he would remit modest personal payments via cash or credit cards; on other occasions, he declined to pay anything whatsoever. Upon returning to Singapore, Chan would ensure these receipts reached relevant administrative personnel within FHC or its subsidiary Fullerton Health China, who would subsequently process them as legitimate corporate expenses.
The operation enjoyed the knowledge and participation of Tan, with both men coordinating aspects of the fraudulent submissions. Documentation presented before the court established that during 2016, Tan, Chan, and Sin jointly conspired to produce falsified entertainment claims, demonstrating that misconduct occurred at multiple organisational levels. The prosecutors' statements illuminated how Fullerton Healthcare Group, which the pair had established in 2010 to deliver medical services through a network of practitioners and specialists while processing insurance claims for clientele, became the vehicle through which these falsifications occurred. Over the subsequent years, the company expanded, with Tan assuming directorial responsibilities at FHG while Chan became president of Fullerton Health China, giving both significant corporate influence to execute the scheme.
The district judge Paul Quan separately approved the prosecution's application for a discharge not amounting to acquittal regarding all corruption-related charges against both Chan and Tan on the same Friday hearing. This procedural mechanism permits future prosecution should new evidence subsequently materialise, leaving the possibility of renewed charges suspended over the accused. The prosecution had explicitly invoked prosecutorial discretion in seeking to withdraw these allegations, a decision that may reflect evidentiary complexities or prosecutorial strategic calculations regarding the broader case architecture. The move suggests authorities determined that the falsification convictions alone adequately addressed the misconduct without pursuing the more grave corruption charges.
This prosecution occurs within a broader pattern of legal accountability at Fullerton Healthcare. In August 2025, David Sin, the third co-founder aged 47, independently pleaded guilty to six counts of falsifying accounts and received an identical S$160,000 fine, suggesting systematic control weaknesses permeated the organisation's financial governance. Sin's case preceded the current sentencing, indicating investigators discovered comparable misconduct across multiple individuals within the company's hierarchy. The progression of cases demonstrates that regulatory authorities have methodically pursued accountability across the founding team, sending clear signals about corporate governance expectations within Singapore's healthcare and professional services sectors.
For Malaysian and Southeast Asian business observers, these prosecutions underscore persistent vulnerabilities in corporate expense management and internal audit frameworks affecting even established regional enterprises. Fullerton Healthcare's international footprint, including operations in China and Singapore, illustrates how expatriate management arrangements and multi-jurisdictional subsidiary structures can obscure financial irregularities. The scheme exploited the frequent international travel that characterises regional healthcare and investment operations, using legitimate business justifications to mask fraudulent documentation flows. Companies operating across multiple Asian markets should note that Singapore's Corrupt Practices Investigation Bureau maintains sophisticated investigative capabilities and that entertainment expense claims receive elevated scrutiny in sectors susceptible to relationship-based business development.
The implications extend beyond immediate punishment to corporate governance architecture. Both Chan and Tan have relinquished their operational positions within FHC's subsidiary companies, effectively removing them from decision-making roles. This represents a significant career consequence for experienced physicians who had built substantial regional healthcare enterprises. The case demonstrates that regulatory authorities increasingly expect senior executives to maintain documentation integrity regardless of the underlying purposes for which funds might be redirected, even when beneficiaries claim hardship justifications. Southeast Asian companies engaged in cross-border operations should strengthen expense authorisation procedures, particularly for entertainment and discretionary spending categories that frequently feature in business development activities. The prosecution's willingness to pursue cases methodically across multiple executives signals that corporate culture permitting financial flexibility, regardless of stated charitable motivations, faces sustained legal consequences within Singapore's enforcement environment.
